Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$232.94
Open:$227.01
Day's Low:$221.59
Day's High:$230.41
Bid / Ask:-
Market Cap:31.94B
Enterprise Value:32.36B
52-Week Range
52-Week Low:$180.27
52-Week High:$277.67
Current position in 52-week range
52w Low-52w High
50-Day Avg:$231.82
200-Day Avg:$224.75
Volume
Volume Today:2,136,672
Avg Volume (3m):1,355,703
Avg Volume (10d):1,443,460
52-Week Change:-5.46%
vs S&P 500, 52 weeks:-
Beta:0.76
Valuation Multiples
P/E (trailing):20.68
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
P/E (forward):17.14
PEG Ratio:1.25
Price / Book:5.37
Price / Sales (TTM):5.57
EV / Revenue:5.65
EV / EBITDA:15.22
Dividends
Current yield:1.13%
Annual Dividend Rate:$2.64
Dividend Trailing:$2.46
Yield Trailing:1.06%
5-Year Avg Yield:0.87%
Payout Ratio:22.40%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):5.73B
Gross Profit:3.54B
EBITDA:2.13B
Net Income (TTM):1.59B
Rev Growth (YoY):+5.90%
Earnings Growth (YoY):+23.20%
Quarterly earnings growth (YoY):+20.00%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$10.98
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$13.25
Revenue Per Share:$39.61
Cash Per Share:-
Book Value:$42.29
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:1.01B
Total Debt:610.58M
Net Debt (Debt - Cash):−400.16M (net cash)
Debt / Equity:10.27%
Current Ratio:2.65
Quick Ratio:1.54
Cash Flows
Operating Cash Flow:1.77B
Free Cash Flow (FCF):1.30B
FCF Yield (FCF / Market Cap):-
Enterprise Value:32.36B
EV / Revenue:5.65
EV / EBITDA:15.22
Profitability
ROE (Return on Equity):26.40%
ROA (Return on Assets):14.76%
P/E (trailing):20.68
P/E (forward):17.14
Price / Book:5.37
PEG Ratio:1.25
52-Week Change:-5.46%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$10.98
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$13.25
P/E (forward):17.14
PEG Ratio:1.25
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$39.61
Cash Per Share:-
Book Value:$42.29
Cash Flows (TTM)
Free Cash Flow:1.30B
Operating Cash Flow:1.77B
EBITDA:2.13B
Total Revenue (TTM):5.73B
Net Income (TTM):1.59B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:140,657,071
Float (free shares):139,828,601
Short interest (shares):11,920,328
Short % of float:-
Short Ratio (days to cover):10.34
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
ResMed Inc. (RMD) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD
Founder, Chair Emeritus & Non-Executive Director
83
420,863
Mr. Aaron Bloomer
Chief Financial Officer
39
823,929
Mr. Michael J. Rider
Chief Legal Officer & Secretary
67
915,486
Mr. Brett A. Sandercock
Advisor
58
1.29M
Mr. Justin Leong
Chief Product Officer
48
1.46M
Mr. Alastair Robertson
Chief Information Officer
-
-
Ms. Sallilyn Schwartz
Chief Communications & Investor Relations Officer
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
ResMed Inc. (RMD): Quantitative Analysis
ResMed Inc. (RMD) — Healthcare — Medical Instruments & Supplies. RMD is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, RMD has returned −5.0% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
RMD ranks 278 of 461 on today's multifactor score, and 39 of the 55 Healthcare companies that score. Its strongest factor is quality (Z 0.77, ranked 40 of 468); its weakest is momentum (Z -0.66, ranked 362 of 494). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
ResMed has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 after the close (SEC filings through Oct 29, 2026). RMD earnings dates and times, quarter by quarter →
What is ResMed's P/E ratio?
ResMed's P/E (price over earnings per share for the last twelve months) is 20.7 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: ResMed is below its sector median. Healthcare stocks, company by company →
Where does ResMed rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, ResMed ranks 278 of 461, and 39 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have ResMed insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of ResMed shares from August 2025 through Nov 3, 2026. The latest sale was on Oct 23, 2026, by an officer, for $102k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 37 sales by directors, officers and large shareholders. All RMD insider trades →
Does ResMed pay a dividend?
Yes. Its dividend yield is 1.13% at the Nov 3, 2026 close (annual dividend of $2.64 per share). The next announced ex-dividend date is Nov 12, 2026.
What sector is ResMed in, and which index?
ResMed is classified in the Healthcare sector (industry: Medical Instruments & Supplies), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.